Protara Therapeutics has touted a 66% complete response (CR) rate for its cell therapy among certain bladder cancer patients ...

The interim analysis of the BCG-Unresponsive cohort includes 35 evaluable participants, of whom, 22 were evaluable at six months and 15 were evaluable at 12 months as of a January 28, 2026 data cutoff ...

Bladder cancer frequently announces itself through symptoms that patients dismiss as minor urinary issues, and that delay ...

Draft guidance from NICE recommends durvalumab before and after surgery for muscle-invasive bladder cancer following phase 3 trial survival data.

What Is Zusduri Used For? Zusduri is used to treat a certain type of recurrent, persistent bladder cancer known as LG-IR-NMIBC. About 75% of people with bladder cancer present with non-muscle invasive ...

Protara Therapeutics (TARA) stock drops as the company updates data from a mid-stage trial for its lead candidate TARA-002 in ...

ImmunityBio Inc. IBRX shares are up on Monday following the company’s announcement of significant revenue growth. • ...

Non-muscle invasive bladder cancer is cancer that’s only in the inner lining of your bladder. It hasn’t grown into the muscle wall. Your doctor may also call it superficial bladder cancer, urothelial ...

This Press Release identifies that Dr. Kulkarni has participated in a medical advisory position for Theralase(R) in the ...

Despite their renal and cardiovascular protection, GLP-1RA vs SGLT2i carries somewhat higher risks of renal cell carcinoma and urothelial cell carcinoma in adults with type 2 diabetes. The risks of ...

Bladder cancer affects over 52,000 men and women in the United States on an annual basis, and more than 12,000 people die each year from this disease. It is the fourth most common cancer in men in ...